双香豆素和保泰松抗凝作用增强的理解（Enhanced dicoumarin and phenylbutazone anticoagulation understanding）.docVIP

双香豆素和保泰松抗凝作用增强的理解（Enhanced dicoumarin and phenylbutazone anticoagulation understanding） Anticoagulant 1 heparin: both in vivo and in vitro have a strong anticoagulant effect, which is achieved by antithrombin III, and has many inhibitory effects on the coagulation process, and its action is rapid. The formulation is only intravenous administration, because of easy to use (subcutaneous injection), commonly used in rapid anticoagulant therapy or as an oral anticoagulant medication before, when excessive amount of bleeding, amount of protamine and available. Long term use of heparin is associated with increased risk of bleeding and side effects. Heparin anticoagulant: 1, 3 (1): enhanced with thrombin antithrombin affinity, accelerate thrombin inactivation; (2) adhesion and inhibit platelet aggregation; (3) enhancing activity of C protein, stimulate vascular endothelial cells release anticoagulant and fibrinolytic substances. 2, inhibit platelet, increase the permeability of blood vessel wall, and regulate angiogenesis. 3, with the role of regulating blood lipids. 4, it can act on many links of the complement system to inhibit the over activation of the system. Associated with this, heparin also has anti-inflammatory and antiallergic effects. Low molecular weight heparin: [pharmacological action] factor has little effect on the activity of a, thrombin and other coagulation factors. The anticoagulant activity due to the A / live system so that the heparin antithrombin depolymerization by chemical or enzymatic method and average molecular weight is about 4 ~ 6kD. Selective anticoagulant ratio is generally 1.5 to 4, while the ordinary heparin is about 1, the lower the molecular weight, anti coagulation factor X A activity is stronger, which makes the antithrombotic effect and bleeding effect separation, maintain the antithrombotic effect of heparin and reduce the risk of bleeding. [anti clotting factor X A activity t1/2] pharmacokinetics of low molecular weight heparin. Wa